A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
Condition studied
Ulcerative colitis (Inflammatory Bowel Disease)
Investigational medicinal product(s)
SPYPBO-101SPY001-001SPY002SPY003
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Incidence of TEAEs (treatment-emergent adverse event)
Endpoint detail
Endoscopic improvement at Week 48
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.